In conclusion, we find that by producing more and more positive results in very sensitive assays one does blur the picture of myositis-specific autoantibodies and diminishes their diagnostic value.

Correspondence to: Dr Mierau

Author's reply

The conclusion of Drs Mierau, Dick, and Genth that by producing more and more positive results in very sensitive assays one blurs the picture of myositis-specific autoantibodies and diminishes their diagnostic value is not correct. The autoantibody specificities we measured remain very specific for myositis and as such still are a useful help for diagnosis. However, our data indeed show that anti-Mi-2 antibodies are not completely specific for dermatomyositis (DM) as has been suggested so far, but also occur in 9% of patients with polymyositis (PM). We explained this result by the fact that we used the complete Mi-2 protein (in four overlapping fragments) as antigen, whereas in all previous studies the NM fragment, containing only 26% of the protein, was coated in the enzyme linked immunosorbent assay (ELISA) assay.

Mierau and colleagues argue that we did not provide information on the diagnostic specificity of the Mi-2 assay we used. The test, in fact, using the four overlapping fragments was evaluated with healthy subjects by testing 84 samples from blood donors. The absorbance values at 405 nm of the mean plus 3SD were 0.262 for the NT fragment, 0.450 for the CT fragment, and 0.500 for both the NT and M fragments, and 0.450 for the CT fragment. When this design with rather high cut off values is used, these new tests are specific for the blood donor samples used. To strengthen the argument that anti-Mi-2 antibodies do occur in a significant percentage of PM we successfully confirmed about 50% of the Mi-2 positives by immunoblotting. Because ELISA is much more sensitive than immunoblotting, or one of the other techniques mentioned by Mierau and colleagues, at this stage of our research we have to accept the fact that 100% confirmation cannot be reached. Our results thus show that anti-Mi-2 is not as specific for DM as it hitherto thought. The take home message for the clinician is that when anti-Mi-2 autoantibodies are found, the underlying disease might not necessarily be DM.

Mierau and colleagues also correctly state that reported coincidences of myositis-specific antibodies are rare. In our study, testing healthy controls and patients without containing many patients, such coincidences were found more often, as expected, albeit still in a very low percentage of the patients. Again we think that we found these coincidences by virtue of the very sensitive assays we used for the detection of anti-Mi-2 and anti-SRP antibodies. We disagree, however, that such results inevitably mean a loss in specificity.

Apart from the biochemical refinements mentioned above, there could be a second reason for the discrepancy between previous studies and our results, and that is the problem of adequate diagnosis, as Mierau, Dick, and Genth suggest. In our study we distinguished PM from inclusion body myositis (IBM), which was not the case in previous studies on autoantibody associations. We used established criteria for the diagnosis PM, DM, and IBM. In addition, when anti-Mi-2 autoantibodies were found, patients were, to enable comparison with previous studies, also classified according to the criteria published by Bohan and Peter, which, however, did not change the diagnosis.

In conclusion, using more sophisticated serological analyses and precise clinical classifications based on established criteria in a large group of patients with myositis, we found that the presence of anti-Mi-2 antibodies is not as exclusive for DM as has been suggested in the past. Instead of blurring the picture of myositis-specific autoantibodies, we may have corrected it.

W J VAN VENROOIJ

Department of Biochemistry,
University of Nijmegen,
Nijmegen, The Netherlands


**Usefulness of the HAQ in the clinic**

Greenwood et al have questioned the usefulness of the Stanford Health Assessment Questionnaire (HAQ) in the clinic.¹ Using Bland and Altman’s limits of agreement procedure,² they report that an HAQ score change of at least 0.48 units is required to confidently reflect significant change. We have used the HAQ in the care of our patients for many years and think that their conclusions about the extent of change required and the non-usefulness of the HAQ in clinical care is not correct.

We have replicated the authors’ study in paired visits of 443 patients with rheumatoid arthritis (RA) followed up in the clinic by one of us (FW) in a survey databank of 2720 patients. Our data are in general agreement with the authors’ data.

Using the limits of agreement procedure, we found that the 95% confidence intervals (CI) for the HAQ were approximately 0.9 for clinical data and 0.6 for survey data. But we also found the following. To exceed 95% CI, changes in excess of 40 mm/1st h for the erythrocyte sedimentation rate (ESR), 70 mm Hg for grip strength, 10 joints for a joint count, and four units on 0–10 VAS scales for pain, global severity, and fatigue were required.

Although clinicians may have trouble in interpreting HAQ scores, there is no doubt that one does not need a change of 40 mm/1st h for ESR, 70 mm Hg for grip, or 10 joints to detect clinical change. These data, which indicate that we cannot reliably do what we are already reliably doing, suggest two interpretations. Firstly, stable measures of overall health are themselves noisy and do not reflect changes in arthritis clinical status. Secondly, we suggest that the Bland–Altman method for agreement and reliability may not work well and may not have a simple interpretation when extrapolated to settings such as these.

In additional analyses that measured relative accuracy and precision, we examined all of the above variables as well as the SF-36 and WOMAC variables using Lin’s concordance coefficient.³ The HAQ was the most accurate and precise of all of the above variables, with concordance correlations of 0.809 and 0.902 in the two analytic sets.

We also believe it is a mistake to use the HAQ in isolation. One would not treat RA with a sedentary rate of C-reactive protein (CRP), or joint count alone, and the HAQ should not be used in that manner. In our clinics we collect HAQ, pain, global severity, joint counts, and ESR/CRP, and we use all of these data together to understand the status of the patient. One simple way to do this is to assign 1 or 0 or 1 to respective negative, neutral, and positive changes in the various variables, and then to add up the individual values. Scores of three or above are associated with significant, clinically important change. Clinicians generally go further and look at the magnitude of the changes to improve further the usefulness of these tests, and for research purposes it is possible to develop a combined standardised score that documents these changes. But clinicians are also Bayesians, and use the HAQ and other clinical measures with knowledge of the particular patient and his longitudinal pattern of responses for each separate variable. We suggest that when the HAQ is used in this manner it provides continuing clinically useful information.

Scientific research in chronic rheumatic diseases will benefit when the clinical investigator brings to the research table the same longitudinal, Bayesian, non-linear insights that the clinician has long had and has long used. The HAQ works in the clinic when used and interpreted appropriately.

**References**


**Letters to the editor**

**Multinodular goitre with giant cell vasculitis of thyroid arteries in a woman with temporal arthritis**

Previous studies have suggested that patients with giant cell arthritis (GCA) or polymyalgia rheumatica (PMR) may be at increased risk for thyroid dysfunctions.¹ To our knowledge, histologically confirmed thyroid arthritis in a case of GCA has never been described.

A 67 year old woman, complained in September 1994 of left sided headaches, jaw claudication, and transient visual disturbance of her left eye. Biological evaluation showed an increase of inflammatory process, and biopsy of the left temporal artery was typical of GCA. Steroids were started (1 mg/kg/day prednisolone) with initial clinical and biological improvement, but a steroid dependency was noted when the dose was reduced to under 40 mg/day. On successive clinical evaluations, we noticed an increase in the volume of the thyroid gland. Ultrasonography showed a multinodular goitre with heterogeneous nodules characterised by either cystic or solid appearance. Thyroid function tests were normal and a search for antithyroid antibodies (antimicrosomal and antithyroglobulin antibodies) was negative.

Owing to the increase in volume of the goitre and the increased number of nodules (the largest nodule measured 2.5 cm), a total thyroidectomy was performed in February 1997 (29 months after the onset of temporal arthritis). Histopathological analysis concluded that there was a multinodular goitre with benign adenomas. Analysis of the left superior thyroid artery showed an inflammatory granulomatous lesion with giant cells in the elastica externa (fig 1), whereas the right superior thyroid artery was normal. At that time, the patient was treated with prednisolone (20 mg/day) and there was a mild biological inflammatory process (erythrocyte
and female genital tract arteries. Treatment with methotrexate (10 mg/week), and L-thyroxine (125 µg/day) was continued.

At her last medical visit in April 2000 the clinical and biological outcome was good without any sign of relapse in the GCA. Treatment with prednisone (2 mg/day), methotrexate (10 mg/week), and L-thyroxine (125 µg/day) was continued.

Assessments of thyroid dysfunctions and GCA have included hypothyroidism,\(^8\) thyrotoxicosis,\(^4\) Graves’s disease,\(^5\) and de Quervain’s thyroiditis.\(^6\) In the series of Bowness et al of 10% of the 367 patients with PMR or GCA, or both, had antithyroid autoantibodies and 4.9% had clinical and biochemical hypothyroidism requiring replacement therapy with thyroxine, which was significantly greater than in the control group.\(^7\) To explain the association between PMR and/or GCA and autoimmune thyroid diseases, the authors suggested a common aetiological agent (perhaps infective) or a common immunological predisposition. However, a recent multicentre case-control study on 285 patients with GCA failed to show a significant relation with thyroid diseases.\(^3\)

The involvement of non-classical organs in GCA with histologically proved vasculitis has been reported for coronary, renal, hepatic, and female genital tract arteries.\(^8\) As thyroid arteries are branches of the external carotid artery, the occurrence in our observation of GCA and nodular goitre with thyroid arteritis was probably not fortuitous. Moreover, GCA was seen on the same side of the head and neck (respectively left temporal artery and left superior thyroid artery). To our knowledge, only one previous observation of an inflammatory infiltrate in the thyroid gland, comprising multinucleated giant cells, has been reported and concerned subacute thyroiditis occurring simultaneously with GCA.\(^9\) As the sample was obtained by thyroid aspiration, the author could not conclude that there was GCA involvement.\(^8\)

From a pathophysiological point of view we feel that, in our case, thyroid ischaemic lesions (often seen in goitres)\(^10\) and/or inflammatory infiltrate induced by the vasculitis process may have played a part in the formation of the goitre. Thus a possible link between GCA and goitre must be kept in mind.

Giant cell arteritis associated with demyelinating polyradiculoneuropathy

Peripheral nerve involvement—mononeuritis,\(^4\) mononeuritis multiplex, and polyneuropathies—has been reported in 14% of patients with giant cell arteritis (GCA).\(^3\) GCA associated with acute inflammatory demyelinating polyneuropathy (AIDP) has exceptionally been described.\(^3\) We report an unusual case of this association.

A 67 year old woman presented with a one month history of difficulty in walking, weakness, and proximal myalgia that worsened progressively. Examination showed proximal weakness and abolition of all deep tendon reflexes; there was no sensory deficit and cranial nerve function was normal. Laboratory tests disclosed normal haematological findings with an erythrocyte sedimentation rate (ESR) of 12 mm/1st h; renal and liver function tests, muscle enzymes, and thyroid stimulating hormone were in the normal range. Serum protein electrophoresis, anti-nuclear antibodies and rheumatoid factors, and serology for Lyme disease, Q fever, mycoplasma, Venereal Disease Research Laboratory test, HIV, and cytomegalovirus were all negative. Chest radiographs and abdominal echography were normal. Electrophysiological investigation disclosed an inflammatory demyelinating polyradiculoneuropathy, with prominence of motor and proximal involvement. The cerebrospinal fluid (CSF) showed four mononuclear cells/ml; protein 0.56 g/l and glucose 3.4 mmol/l.

At this moment, an AIDP or Guillain-Barré syndrome was diagnosed, and plasma exchange was performed, using standard procedures. After the second plasma exchange, the weakness had completely disappeared, but the patient started with fever (40°C) and increasing bitemporal and ocular pain. Thus an AIDP was suspected.

Laboratory tests revealed: haemoglobin 9.8 g/l; white blood cell count 11.8×10⁹/l; platelet count 340×10⁹/l; ESR 44 mm/1st h; C reactive protein 10 mg/l. A search for antinuclear antibodies, anti-extract cell antigen, and antithyroid antibodies as well as lupus anticoagulant was negative. Treatment with prednisone (2 mg/day), methotrexate (10 mg/week), and L-thyroxine (125 µg/day) was continued.

Figure 1 Histopathological analysis of thyroid gland (haematoxylin-eosin-saffron, original magnification ×250). Giant cells and granulomatous inflammatory infiltrate near fragmented elastic tunica.

progression of the demyelinating polyradiculoneuropathy. She had no other symptoms. Haematological and blood chemical findings were all normal, as was the ESR. Plasma exchange sessions were restarted. The diagnosis at this time was an AIDP relapsing form. Prednisone was given at 1 mg/kg weight. She improved rapidly. Because of the serious side effects she had previously had with the steroid treatment (30 kg weight gain, hyperglycaemia, mental changes) and the poor vascular access she had for the plasma exchange, we decided to start treatment with intravenous immunoglobulin pulses, 0.4 g/kg weight every four weeks. Steroids were tapered and the patient remained clinically well during the following years.

To our knowledge, only two cases of GCA associated with AIDP have been previously reported (table 1), and no association of GCA with the AIDP relapsing form has been previously described. The first case refers to a patient who presented a clinical picture of AIDP and in whom temporal arteritis was diagnosed two weeks later.1 In the second case the patient was diagnosed as temporal arteritis,2 with a compatible biopsy; he was treated with prednisone and four weeks later he presented a generalised weakness: CSP and electrophysiological study were concordant with AIDP. A sural nerve biopsy was not done in these cases.

The neuropathies associated with temporal arteritis and other vasculitides have been attributed to ischaemic lesions of the nerves due to an arteritis of the vasa nervorum. A vasculitic neuropathy was excluded in our case because the clinical course and the electrophysiological study were characteristic of AIDP.

The underlying cause and pathogenic mechanisms of AIDP and GCA are not well understood. Immune cellular mechanisms have an important role: an increasing number of T CD4+ cells and macrophages in demyelinated regions of the nerve are seen in AIDP. The histopathology of GCA shows a mixed inflammatory infiltrate with T CD4+ lymphocytes and macrophages secreting proinflammatory cytokines.3

Temporal arteritis associated with inflammatory demyelinating polyradiculoneuropathy may be a coincidence, but a common immunological pathogenesis, probably based on a cellular T cell dependent mechanism and related to a cytokine deregulation, cannot be ruled out. Infectious agents, such as a virus, may be the cause of the onset of both diseases in a subset of patients.3

Oral steroid in the treatment of carpal tunnel syndrome

A range of options are available for the conservative treatment of carpal tunnel syndrome (CTS).1,4 Non-operative methods include immobilisation of the affected hand with wrist splint; local injection of steroids and drugs such as diuretics and non-steroidal anti-inflammatory drugs.4,5 These oral drugs are thought to decrease the volume of swollen tissue within the CTS and are widely used, but there is limited clinical evidence for their role.

This prospective randomised, double blind, placebo controlled study aimed at evaluating the effect of oral steroids in the symptomatic treatment of CTS. We recruited patients with newly diagnosed CTS of more than three months’ duration with confirmatory electrophysiological results (prolonged median nerve distal motor latencies >4 ms or median ulnar palmar sensory latency difference >0.5 ms) including electromyographic recordings of the abductor pollicis brevis (APB); co-interventions such as drug or injection treatment were withheld during the study. Exclusion criteria included (a) patients with evidence of severe CTS: fibrillation potentials or reinnervation on needle examination of the APB, (b) coexisting disorders or conditions which may mimic CTS, such as cervical radiculopathy or peripheral neuropathy, (c) contraindication to steroid use; and (d) history of underlying disorders associated with CTS, such as diabetes mellitus or rheumatoid arthritis.

Patients who fulfilled the criteria were treated conservatively for two months with splinting. If symptomatic after this period, patients were allocated, using a random computer generated code, to a 10 day course of prednisolone 25 mg/day or a 10 day course of placebo. Both were given as single tablets which were identical in appearance. A physician (SMW) unaware of the treatment allocation assessed the mean global symptom score (GSS) of all patients at two and eight weeks. This is a scoring system first devised by Hershkoviz which rates symptoms on a scale of 0 (no symptoms) to 10 (severe) in five categories: pain, numbness, paraesthesia, weakness/clumsiness, and nocturnal awakening. The sum of the scores in each category was the GSS.6 Median (interquartile range (IQR)) changes in GSS at two and eight weeks from baseline were analysed for detecting a 50% difference in GSS between the treatment groups, assuming

Table 1

<table>
<thead>
<tr>
<th>Case 1*</th>
<th>Case 2*</th>
<th>This study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age/sex</td>
<td>71/female</td>
<td>73/male</td>
</tr>
<tr>
<td>Headache</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Fever</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Visual loss</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Facial diplegia</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>PMR+ symptoms</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Latency between GCA+ and PN*</td>
<td>AIDP* occurred 2 weeks before GCA</td>
<td>GCA preceded AIDP by 4 months</td>
</tr>
<tr>
<td>Laboratory tests</td>
<td>125 Protein 0.1 g/l; acellular</td>
<td>125 Protein 3 g/l; acellular</td>
</tr>
<tr>
<td>ESR* (mm/1st h)</td>
<td>Normal</td>
<td>GCA</td>
</tr>
<tr>
<td>Temporal artery biopsy</td>
<td>Prednisolone, 80 mg/day</td>
<td>AIDP</td>
</tr>
<tr>
<td>Nerve conduction study</td>
<td>Spontaneous improvement of the AIDP symptoms of GCA were controlled with steroids</td>
<td>TIA during GCA prednisone treatment</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone was given at 1 mg/kg weight every four weeks. Steroids were tapered and the patient remained clinically well during the following years.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PMR = polymyalgia rheumatica; GCA = giant cell arteritis; PN = polyneuropathy; ESR = erythrocyte sedimentation rate; CSF = cerebrospinal fluid; AIDP = acute inflammatory demyelinating polyradiculoneuropathy; PEX = plasma exchange; TIA = transient ischaemic attack; IVIg = intravenous immunoglobulin.

Correspondence to: Dr M Yebra Bango, Servicio de Medicina Interna I, Clínica Puerta de Hierro, C/ San Martin de Porres No 4, 28035 Madrid, Spain

M GARCÍA GASALLA
M YEBRA BANGO
JA VARGAS NÚÑEZ
S MELLOR PITÀ
M GARCÍA ALVARADO
A DE ABAYO ALONSO
Department of Internal Medicine, Clínica Puerta de Hierro, Madrid, Spain

G GOIZUETA
Department of Neurophysiology

References


www.annrheumdis.com

Downloaded from http://ard.bmj.com/ on June 15, 2017 - Published by group.bmj.com
the response rate in the oral steroid group to be 80% and that of the placebo group 30%.

Thirty-six patients were recruited, of whom half were randomly allocated to receive oral steroids and half to placebo. There was no significant difference in demographics such as age and in the severity of electrophysiologically parameters as shown in table 1. As compared with baseline, patients receiving steroid had a median (IR) change of −12.5 (−15 to −7) at two weeks, whereas the placebo group had a median (IR) change of −4.5 (−14 to 0), p=0.027 as shown in fig 1A. After eight weeks, the median (IR) reduction of GSS in the steroid group was −9 (−14 to −6) and in the placebo group −2 (−10 to 0), p=0.034 as shown in fig 1B. The median differences between the two groups at two and eight weeks were −6 (−11 to −1) and −6 (−11 to 0) respectively. All patients completed the short course of treatment.

This study shows a small but statistically significant reduction in GSS in the group prescribed a short course of prednisolone as compared with placebo. Steroid may have a role in the treatment of mild to moderate CTS in patients who decline or who are awaiting surgical decompression. Further trials with larger sample size and longer follow up, using low dose oral steroid in direct comparison with placebo would further clarify the effect of this treatment.

CTs with moderate to severe symptoms were treated with steroid in combination with other measures and splint use. Arch Phys Med Rehabil Clin Proc 1989;64:829–36.

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Steroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient numbers</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Age, years (mean (SD))</td>
<td>44.9 (10.0)</td>
<td>42.9 (7.2)</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>17/1</td>
<td>17/1</td>
</tr>
<tr>
<td>Baseline GSS*, (median, IR*)</td>
<td>24 (16–26)</td>
<td>20 (18–26)</td>
</tr>
<tr>
<td>CMAP amplitude, mV (mean (SD))</td>
<td>12.95 (3.40)</td>
<td>14.49 (3.01)</td>
</tr>
<tr>
<td>Dorsal motor latencies, ms (median (IR))</td>
<td>5.08 (1.20)</td>
<td>4.97 (0.84)</td>
</tr>
<tr>
<td>Location of CTS*</td>
<td>Right 10</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Left 2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Bilateral 6</td>
<td>6</td>
</tr>
</tbody>
</table>

*GSS = global symptom score; IR = interquartile range; CTS = carpal tunnel syndrome.

Parvovirus B19 infection in Behçet’s disease

We read with great interest the article by Kerr which reviewed present knowledge about the possible association of parvovirus B19 infection with various connective tissue and autoimmune disorders.1 The author concluded that data implicating B19 virus infection in the aetio-pathogenesis of these disorders is insufficient and conflicting. Although a significant number of studies support a possible role for the virus in the pathogenesis of rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus, and vasculitis, the author believes that B19 infection is only one of a number of triggers.

Behçet’s disease (BD) is a multisystem disorder originally described by the Turkish dermatologist Hulusi Behçet. As stated by the author, various case reports have been published demonstrating the presence of B19 virus in patients with vasculitic syndromes.1 Viral infections have also been postulated as triggering factors in BD. Therefore, in a previous study that was not cited in the report by Kerr, we investigated a possible role of B19 virus in BD.2 We assessed antibodies against parvovirus B19 in serum samples from 41 patients with BD and from 40 age and sex matched controls. Six patients with BD (15%) had anti-B19 IgM antibodies while no IgM antibodies were detected in the control group (p=0.03). However, anti-B19 IgG antibodies were present in 23 patients with BD and 25 controls. There was also no correlation between the presence of anti-B19 IgM antibodies and articular and vascular manifestations of BD (p=0.9 and p=0.5, respectively).

We concluded that our findings did not strongly support the involvement of B19 in the pathogenesis of BD, and we also concluded that serological evidence of acute B19 infection in six patients with BD might have been coincidental. However, the presence of anti-B19 IgM antibodies in patients with BD might provide evidence for the place of B19 infection in the pathobiology of BD. As far as we know our previous report is the only published study investigating the association of B19 virus infection and BD. Therefore, further studies will be clearly needed to clarify this unresolved issue.

Idiopathic dilatation of the pulmonary artery in a patient with dermatomyositis complicated by interstitial pneumonitis

Idiopathic dilatation of the pulmonary artery (IDPA) is an uncommon anomaly occurring in 0.6% of patients with congenital heart disease, and may be bilateral or unilateral. We report on a patient with IDPA who concomitantly developed polymyositis (PM) and interstitial pneumonitis (IP).

On 25 August 1997 a 63 year old woman was referred to our hospital because of dyspnoea, pyrexia, arthralgia, raised levels of creatinine kinase (CK; 2078 IU/l), and aldolase (40.3 mm Hg). Prednisolone (40 mg/day) was started from 17 September. The fever subsided, and the laboratory data improved on the day of discharge (31 October). LDH decreased from 1082 to 738 IU/l, CK from 1885 to 223 IU/l, AST from 60 to 18 IU/l, ESR from 116 to 27 mm/1st h, and white blood cell count from 19 000 to 9600/µl.

Data of pulmonary function tests including BGA were unchanged. While taking 30 mg prednisolone a day, she visited crowded stores and thereafter developed pyrexia with severe dyspnoea. BGA showed hypoxaemia (Pao, 45.2 mm Hg and Paco, 35.5 mm Hg). Laboratory data on readmission showed LDH 1881 IU/l, CK 169 IU/l, AST 25 IU/l, ESR 122 mm/1st h, C reactive protein 212 mg/l, white blood cell count 15 100/µl, and platelets 60 000/µl.

We diagnosed her as having IDPA complicated with PM related IP.

Arthritis associated with non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis (NASH) is an entity characterised by mild abnormal liver function tests, a negative serological investigation, and histopathological findings similar to those seen in alcohol induced liver disease in patients who do not consume significant amounts of alcohol. Patients are usually asymptomatic but may complain of fatigue, malaise, or vague right upper quadrant discomfort. A low calorie diet is helpful in most of these patients. We present a case report of a patient with arthritis associated with NASH, which resolved completely after the introduction of a low calorie diet.

A 37 year old man presented with symmetrical arthritis during the past year affecting the elbows, wrists, shoulders, and knees. He had morning stiffness, which resolved after a one hour period of activity. On physical examination there was moderate tenderness of the elbows and wrists without swelling or limitation of the range of motion. Liver and spleen were not enlarged. Laboratory studies showed increased liver enzymes; aspartate aminotransferase 65 IU (normal <49 IU), alanine aminotransferase 52 IU (normal <51 IU), glutamyl transpeptidase 37 IU (normal <34 IU), alkaline phosphatase 64 IU (normal <131 IU), and total bilirubin 16 µmol/l. Serum cholesterol was 6.00 mmol/l, triglycerides 1.62 mmol/l, total protein 77 g/l, and albumin 50 g/l.

Sedimentation rate was 20 mm/1st h, C reactive protein was normal, rheumatoid factor, antinuclear antibodies (ANA), hepatitis B surface antigen, and antibodies to hepatitis C virus (HCV), smooth muscle antibodies, and mitochondria were all negative. He had IgG antibodies to antikeratin antibodies.
antibodies to Epstein-Barr virus, and cytomegalovirus. An x-ray examination of the hands and knees was negative. An ultrasound of the liver and spleen was normal.

His primary physician reported that the abnormal liver function tests had been present for approximately two years. A liver biopsy showed prominent macrovesicular fatty changes, aggregates of parenchymal inflammation, and mild fibrosis with minimal inflammatory infiltrate at some of the portal spaces. Fibrosis and Mallory bodies were not seen at the central vein areas. Iron staining was negative. These findings are consistent with a diagnosis of NASH.

The patient started on a low calorie diet and a few weeks later his liver function tests normalised with complete resolution of his joint symptoms. A few months later he stopped following the low calorie diet and within one week he began to have joint symptoms and the liver enzymes were found to be raised. Reintroduction of the low calorie diet again resulted in complete resolution of his symptoms and abnormal liver function tests.

Polyarthritis or polyarthralgia is one of the extrahepatic manifestations of liver diseases, and many chronic liver diseases are associated with rheumatic diseases. Examples include the association between chronic infection with HCV and mixed cryoglobulinaemia, the association between chronic infection with HCV and Sjögren’s syndrome, and the association of primary biliary cirrhosis and scleroderma.

Immune complexes may be one of the mechanisms of arthralgia associated with liver diseases, and patients with chronic liver disease due to HCV infection have been shown to have an increased prevalence of ANA, rheumatoid factor, and anti-smooth muscle antibodies.

Increasing evidence shows that several cytokines mediate hepatic inflammation and cholestasis in alcoholic and non-alcoholic steatohepatitis. Among these cytokines tumour necrosis factor α (TNFα) is a key factor. So TNFα mediates not only the early stages of fatty liver but also the transition to more advanced stages of liver diseases like steatohepatitis and cirrhosis. On the other hand, TNFα is an important inflammatory disease mediator in a wide spectrum of articular diseases, and inhibition of this cytokine led to a significant improvement of symptoms and signs in rheumatoid arthritis (RA). So TNFα may be a common mediator in NASH and arthritis.

Liver disease, however, may occur owing to connective tissue diseases which cause the joint symptoms, as has been found in patients with RA, Felty’s syndrome, Still’s disease, systemic lupus, giant cell arthritis, polyarteritis nodosa, and polymyalgia rheumatica. Histological liver changes are usually non-specific. Our patient, however, had no evidence of RA or other rheumatic diseases.

There are numerous reports connecting the ingestion of certain food items and arthritis, with symptomatic improvement after the exclusion of certain types of food from the diet (elmination treatment). Dietary supplementation has resulted in mixed results in patients with RA, with no response to the addition of vitamin C, or zinc, but clinical benefits of diets enriched with fish oil or plant oils. Complete remission has been reported with a diet which included chicken and a few weeks later his liver function tests normalised with complete resolution of his symptoms.

We thank Professor Paul Froom for his editorial assistance.

G S HABIB
W R SALIBA
Department of Internal Medicine B, Lady Davis Medical Centre, 1 Michal Street, Haifa 34362, Israel

Correspondence to: Dr Habib gshabib62@yahoo.com


www.annrheumdis.com